Incanthera plc (AQSE: INC), the specialist oncology company focused on transforming cancer treatment, is pleased to announce successful study results for its skin cancer technology, Sol.
Highlights
Sol is a proprietary topical formulation designed to deliver into the skin an active known to prevent the conversion of solar (actinic) keratoses into skin cancer.
- A new refined formulation of Sol demonstrates statistically significant greater dermal delivery compared with four known comparator products
- Confirmation of exceeding bioequivalence compared with oral delivery
The study, run by the University College of London, School of Pharmacy (“SoP”), has demonstrated that Sol affords greater permeation (delivery of the active into the skin) than comparator products.
The study, undertaken over the past few months, was conducted with the aim of comparing the permeability profile of a new refined formulation of Sol against a panel of four known comparator products. The comparator products comprised formulations that contain the same active ingredient over a range of concentrations, with the expectation of delivering the active through the skin for use in other general cosmetic applications.
The results demonstrated that Sol delivered a greater permeation of the active compared to all four assessed commercial products and that difference was statistically significant (p<0.05 at 24h).
In a previous study (Summer 2019), using an identical model of human skin penetration, the results demonstrated that the delivery of the active with Sol exceeded bioequivalence when compared with oral dosing of the same active. The new data from the current study confirm that this new refined formulation of Sol also exceeds bioequivalence.
These results have exceeded the Company’s expectations, demonstrating unequivocally the efficacy of Sol’s formulation in penetrating the skin barrier and reaching the deeper layers where an effective prevention of skin cancer could be achieved.
The Company is delighted with not only the confirmation of Sol’s superior formulation technology capabilities against non-proprietary creams, but also the strength of the data received, which further enhances the data package to potential commercial partners.
These results follow the filing in July 2020 of a new patent protecting Sol for the prevention and treatment of solar keratoses and related cancers of the skin, which if granted, will further extend the life of the patent family protecting Sol to 2041
Commenting on the results of the study, Chairman, Tim McCarthy said:
“We are delighted at demonstrating the clear efficacy advantage that Sol has when compared to other approaches at delivering the active ingredient into and across the dermal barrier.
The level at which the performance of this patented technology has exceeded expectations is extremely encouraging. This is an important step to enable us to move forward negotiations with potential commercial partners.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
The directors of the Company take responsibility for this announcement.
For further information, please contact:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman
+44 (0) 7831 675747
tim.mccarthy@incanthera.com
Simon Ward, Chief Executive Officer
+44 (0) 7747 625506
simon.ward@incanthera.com
Suzanne Brocks, Head of Communications
+44 (0) 7776 234600
suzanne.brocks@incanthera.com
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
+44 (0) 20 7213 0880
Jo Turner/James Lewis
Broker:
Stanford Capital Partners Ltd
+44 (0) 20 3815 8880
Patrick Claridge/John Howes/Bob Pountney
Notes to Editors
Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.
The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.
The Company originated from the Institute of Cancer Therapeutics (“ICT”) at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.
Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com.